Formerly doing business as Photgen Technologies, Provectus Pharmaceuticals, Inc. is a biopharmaceutical company developing therapies designed to target and destroy breast cancer, liver cancer, and metastatic melanoma while eliminating side effects. It is conducting clinical trials of its proprietary drug Provecta (PV-10) for metastatic melanoma and recurrent breast carcinoma. The company is also undergoing clinical studies for its topical agent Xantryl, a treatment for severe psoriasis. Xantryl is a topical gel that targets skin cancers and pre-cancerous conditions, along with chronic, severe skin afflictions. In addition, Provectus develops biotechnologies for licensure to augment vaccine production and detect viruses, including a ‘virus hunter’ method; and over-the-counter skin care products and patented technologies for therapeutic and cosmetic medical devices for licensure. The company was incorporated in 2002 and is based in Knoxville, Tennessee.
